Overall, pending better therapies, anti-IL-1 and anti-IL-6 bDMARDs, along with JAKis, represent an opportunity for patients with VEXAS syndrome, albeit careful monitoring is essential to control disease activity and ensure treatment safety. Here, IL6 is linked to VEXAS syndrome.